Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience.

被引：1
|
作者：
Advani, R
Maeda, L
Hoppe, RT
Breslin, S
Rosenberg, SA
Baer, D
Mason, J
Horning, SJ
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] No Calif Kaiser Permanente, Oakland, CA USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1932.1932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1932
引用
收藏
页码：548A / 548A
页数：1
相关论文
共 50 条
  • [41] Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early-stage Hodgkin's disease (HD): 5-year results of a randomized trial
    Santoro, A
    Bonfante, V
    Viviani, S
    Zanini, M
    Devizzi, L
    Parra, HS
    DiRusso, A
    Soncini, F
    Villani, F
    Valagussa, P
    Bonadonna, G
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1185 - 1185
  • [42] Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease:: Long-term results of a randomized trial of radiotherapy alone
    Dühmke, E
    Franklin, J
    Pfreundschuh, M
    Sehlen, S
    Willich, N
    Rühl, U
    Müller, RP
    Lukas, P
    Atzinger, A
    Paulus, U
    Lathan, B
    Rüffer, U
    Sieber, M
    Wolf, J
    Engert, A
    Georgii, A
    Staar, S
    Herrmann, R
    Beykirch, M
    Kirchner, H
    Emminger, A
    Greil, R
    Fritsch, E
    Koch, P
    Drochtert, A
    Brosteanu, O
    Hasenclever, D
    Loeffler, M
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (11) : 2905 - 2914
  • [43] Radiotherapy versus chemotherapy as consolidative treatment for stage IIIB-IV Hodgkin's disease (HD) in first complete remission or good partial response:: A study of 559 patients (H89 protocol).
    Fermé, C
    Sebban, C
    Berger, F
    Lederlin, P
    Ferrant, A
    Brice, P
    Diviné, M
    Troncy, J
    Voillat, L
    Stamattoulas, A
    Jaubert, J
    Lepage, E
    BLOOD, 1998, 92 (10) : 485A - 485A
  • [44] Very high risk Hodgkin's disease (HD):: ABVD (4 cycles) plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles)(INT-CT) and RT.: Interim results of the GOELAMS H97-GM multicentric randomized trial.
    Andrieù, JM
    Djeridane, M
    Berthou, C
    Desablens, B
    Lacotte-Thierry, L
    Dib, M
    Vigier, M
    Lamy, T
    Le Tortorec, S
    Dugay, J
    Casassus, P
    Legouffe, E
    Ghandour, C
    Maigre, M
    Flesch, M
    Rodon, P
    Maisonneuve, H
    Lucas, V
    Jardel, H
    Audhuy, B
    Colombat, P
    Colonna, P
    BLOOD, 2002, 100 (11) : 216A - 216A
  • [45] Results of the EORTC-GELA H9 randomized trials:: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)
    Thomas, J.
    Ferme, C.
    Noordijk, E. M.
    van't Veer, M. B.
    Brice, P.
    Divine, M.
    Morschhauser, F.
    Carde, P.
    Eghbali, H.
    Henry-Amar, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 27 - 27
  • [46] Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi
    Chisesi, Teodoro
    Bellei, Monica
    Luminari, Stefano
    Montanini, Antonella
    Marcheselli, Luigi
    Levis, Alessandro
    Gobbi, Paolo
    Vitolo, Umberto
    Stelitano, Caterina
    Pavone, Vincenzo
    Merli, Francesco
    Liberati, Marina
    Baldini, Luca
    Bordonaro, Roberto
    Pesce, Emanuela Anna
    Federico, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4227 - 4233
  • [47] NEOADJUVANT CHEMOTHERAPY (CT) AND RADIOTHERAPY (RT) VERSUS RADIOTHERAPY ALONE FOR SUPRADIAPHRAGMATIC CLINICAL STAGE-I-II HODGKINS-DISEASE (CS-I-II HD) PATIENTS WITH UNFAVORABLE PROGNOSTIC FACTORS - THE EORTC STUDY IN 257 PATIENTS (H-5 TRIAL, 1977-1982)
    CARDE, P
    HAYAT, M
    COSSET, JM
    HENRYAMAR, M
    AMIEL, JL
    TUBIANA, M
    CANCER DRUG DELIVERY, 1986, 3 (01): : 86 - 86
  • [48] First results of the EORTC-GELA H9 randomized trials:: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL).
    Noordijk, EM
    Thomas, J
    Fermé, C
    Van 't Veer, MB
    Brice, P
    Diviné, M
    Morschhauser, F
    Carde, P
    Eghbali, H
    Henry-Amar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 561S - 561S
  • [49] High-risk Hodgkin's disease (HD):: ABVD chemotherapy (4 cycles) followed by BEAM-conditioned autologous stem cell transplantation (ASCT) and focal radiotherapy (RT) versus intensive chemotherapy (3 cycles) followed by involved field RT (IF-RT).: Two-year results of the GOELAMS H97-GM multicentric randomized trial.
    Escoffre-Barbe, M
    Hunault-Berger, M
    Desablens, B
    Le Prisé, PY
    Vigier, M
    Lacotte-Thierry, L
    Traullé, C
    Dugay, J
    Legouffe, E
    Lucas, V
    Ghandour, C
    Maigre, M
    Casassus, P
    Le Tortorec, S
    Maisonneuve, S
    Colombat, P
    Colonna, P
    Andrieu, JM
    BLOOD, 2000, 96 (11) : 791A - 791A
  • [50] Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208
    Carol M. Moinpour
    Joseph M. Unger
    Patricia A. Ganz
    Alice B. Kornblith
    Ellen R. Gaynor
    Mindy Ann Bowers
    Gretchen S. Gatti
    Mark S. Kaminski
    Harry Paul Erba
    Ting Wang
    Jihye Yoon
    Oliver W. Press
    Richard I. Fisher
    Journal of Cancer Survivorship, 2017, 11 : 32 - 40
12345